New Labeling Limits Patient Population Of Bayer’s Trasylol
This article was originally published in The Pink Sheet Daily
Executive Summary
Changes are the result of September advisory committee meeting, concerns over renal dysfunction.
You may also be interested in...
Trasylol Could Face Labeling Changes After Joint Advisory Panel
Long-term observational study showing CV-renal risk for Bayer’s Trasylol should be judged in light of potentially inappropriate comparator drugs, FDA says.
Trasylol Could Face Labeling Changes After Joint Advisory Panel
Long-term observational study showing CV-renal risk for Bayer’s Trasylol should be judged in light of potentially inappropriate comparator drugs, FDA says.
JAMA Article Links Increased Long-Term Mortality To Trasylol Use In CABG Patients
Study published in Feb. 7 issue reporting negative mortality results adds to recent safety concerns regarding aprotinin use and renal dysfunction.